Titan Story

<div class='circular--portrait' style='background:#FF0000;color: #F8F8FF;font-size:4em;'>TP</div>
TTNP -- USA Stock  

USD 2.35  0.07  3.07%

Titan Pharma is scheduled to announce its earnings tomorrow. As many retail investors are getting excited about healthcare space, it is fair to recap Titan Pharma outlook under the recent economic conditions. We will evaluate why we are still optimistic in anticipation of a recovery.
Published over two weeks ago
View all stories for Titan Pharma | View All Stories
Is Titan (NASDAQ:TTNP) outlook optimistic based on the recent analyst consensus?
The entity has a beta of -0.2224, which indicates not very significant fluctuations relative to the market. Let's try to break down what Titan's beta means in this case. As returns on the market increase, returns on owning Titan Pharma are expected to decrease at a much lower rate. During the bear market, Titan Pharma is likely to outperform the market. Even though it is essential to pay attention to Titan Pharma current price movements, it is always good to be careful when utilizing equity historical returns. Our philosophy towards measuring any stock's future performance is to check both, its past performance charts as well as the business as a whole, including all available technical indicators. Titan Pharma exposes twenty-one different technical indicators, which can help you to evaluate its performance. Titan Pharma has an expected return of -0.0535%. Please be advised to validate Titan Pharma jensen alpha and semi variance to decide if Titan Pharma stock performance from the past will be repeated at some point in the near future.
What is the right price you would pay to acquire a share of Titan Pharma? For most investors, it would be the price that gives them a wide margin of safety to have minimal downside risk. In other words, most investors are always looking for undervalued stocks. Even if the future performance is not entirely as expected, the loss of holding it is minimized, and the downside risk is negated.
Please read more on our stock advisor page.

How important is Titan Pharma's Liquidity

Titan Pharma financial leverage refers to using borrowed capital as a funding source to finance Titan Pharma ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Titan Pharma financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Titan Pharma's total debt and its cash.

How Titan utilizes its cash?

To perform a cash flow analysis of Titan Pharma, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Titan Pharma is receiving and how much cash it distributes out in a given period. The Titan Pharma cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.
Titan Pharma Net Cash Flow from Operations is very stable at the moment as compared to the past year. Titan Pharma reported last year Net Cash Flow from Operations of 5.66 Million

Is Titan a risky opportunity?

Let's check the volatility. Titan is looking slightly risky at this time. Whether you invest your money or manage your clients' funds, remember that it is easy to forget that behind Titan (NASDAQ:TTNP) stock is an actual business venture. So, do not let stock picking become an abstract concept by ignoring the elementary risk calculations. obtaining a share of a Titan Pharma stock makes you a part-owner of that company.

Our take on today Titan Pharma decline

Value At Risk just dropped to -6.82, may hint at upcoming price decrease. Titan Pharma exhibits above-average semi-deviation for your current time horizon. We encourage investors to investigate Titan Pharma individually to make sure intended market timing strategies and available technical indicagtors are consistent with their estimates about Titan Pharma future systematic risk. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Titan Pharma's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Titan Pharma's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Our Final Takeaway

Although many of the other players in the biotechnology industry are either recovering or due for a correction, Titan Pharma may not be performing as strong as the other in terms of long-term growth potentials. To conclude, as of the 5th of April 2021, we believe Titan Pharma is currently undervalued. It almost neglects market trends and projects significantly high probability of distress in the next two years. However, our latest 30 days buy-sell recommendation on the firm is Strong Sell.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Achuva Shats do not own shares of Titan Pharma. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com